Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas.
Despite major advances in the management of malignant gliomas of which glioblastomas represent the ultimate grade of malignancy, they remain incurable. Indeed, glioblastoma patients have a median survival expectancy of only 14 months on the current standard treatment of surgical resection to the extent which is feasible, followed by adjuvant radiotherapy plus temozolomide given concomitantly with and after radiotherapy (Lefranc et al., J Clin Oncol 23:2411-2422, 2005; Expert Rev Anticancer Ther 6:719-732, 2006; Stummer et al., Neurosurgery 62:564-576, 2008). Accordingly, the present editorial discusses (1) the high cell motility and resistance to apoptosis which characterise glioblastoma growth and malignancy with respect to the failure of conventional therapy, (2) ways to overcome apoptosis resistance and the real hope offered by temozolomide, (3) targeted chemotherapeutic approaches and the disappointing results obtained in monotherapy but their potential in combination therapy, (4) anti-migratory strategies that could supplement conventional therapy notably by inhibiting a new target; the alpha1 subunit of the sodium pump, (5) dendritic cell therapy, (6) cancer stem cell targeting and finally (7) topical therapies and new surgical approaches for more radical resection which could be used to complement multi-modal treatments within a multi-disciplinary approach.
Lefranc
Florence
F
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004351:Drug Resistance; D005909:Glioblastoma / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D009361:Neoplasm Invasiveness / Q000235:genetics / Q000503:physiopathology; D019635:Neurosurgical Procedures / Q000639:trends; D010348:Patient Care Team; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000254:Sodium-Potassium-Exchanging ATPase; D000077204:Temozolomide